Designed for advanced Parkinson’s with poorly controlled motor fluctuations, the infusion delivers steadier levodopa exposure than pills via continuous subcutaneous dosing.
An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson's disease medication delivered through an infusion pump is safe and effective at reducing ...
GlobalData on MSN
Parkinson’s research reaches “pivotal” stage, but barriers remain
Funding and clinical trial-based barriers must be addressed to ensure success on the path to developing a DMT for Parkinson’s.
Treatment with Crexont statistically significantly improved “On” time without troublesome dyskinesia compared with carbidopa/levodopa IR. The Food and Drug Administration (FDA) has approved Crexont ® ...
Very long acting (> 6–8 h) levodopa preparations are still likely to represent the next chapter in the medical treatment of PD. Continuous-infusion levodopa gel, long-acting levodopa pills, ...
A once-a-week Parkinson’s injection could replace multiple daily pills, thanks to a new slow-release formulation developed by researchers. It promises easier treatment, fewer missed doses, and better ...
The FDA approved an oral extended-release formulation of levodopa and carbidopa known as IPX203 (Crexont) to treat Parkinson's disease, Amneal Pharmaceuticals announced Wednesday. The treatment is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results